MX2010014228A - P/gf-1 companion diagnostic methods and products. - Google Patents

P/gf-1 companion diagnostic methods and products.

Info

Publication number
MX2010014228A
MX2010014228A MX2010014228A MX2010014228A MX2010014228A MX 2010014228 A MX2010014228 A MX 2010014228A MX 2010014228 A MX2010014228 A MX 2010014228A MX 2010014228 A MX2010014228 A MX 2010014228A MX 2010014228 A MX2010014228 A MX 2010014228A
Authority
MX
Mexico
Prior art keywords
products
diagnostic methods
drug
companion diagnostic
methods
Prior art date
Application number
MX2010014228A
Other languages
Spanish (es)
Inventor
D Tyner Joan
C Sogin David
N Ziemann Robert
Datwyler Saul
J Hawksworth David
M Laird Don
L Pucci Dominick
R Lesniewski Richard
Mary McKeegan Evelyn
Original Assignee
Abbott Laboratories Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/485,114 external-priority patent/US8741287B2/en
Application filed by Abbott Laboratories Star filed Critical Abbott Laboratories Star
Publication of MX2010014228A publication Critical patent/MX2010014228A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The present disclosure relates to, among other things, methods for determining whether a subject receiving treatment with a drug has obtained an efficacious blood level of the drug. Moreover, the present disclosure also relates to methods of determining whether a subject predisposed to or suffering from a disease will benefit from treatment with a drug, and the response of a subject receiving treatment (e.g., such as for cancer) by monitoring biomarkers of angiogenesis. In particular, the disclosure relates to P/GF-1 companion diagnostic methods and products.
MX2010014228A 2008-06-18 2009-06-17 P/gf-1 companion diagnostic methods and products. MX2010014228A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7362408P 2008-06-18 2008-06-18
US8917208P 2008-08-15 2008-08-15
US11006308P 2008-10-31 2008-10-31
US12/485,114 US8741287B2 (en) 2008-06-18 2009-06-16 PlGF-1 assay and kits and components thereof
PCT/US2009/047714 WO2009155381A1 (en) 2008-06-18 2009-06-17 P/gf-1 companion diagnostic methods and products

Publications (1)

Publication Number Publication Date
MX2010014228A true MX2010014228A (en) 2011-03-29

Family

ID=41434433

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010014228A MX2010014228A (en) 2008-06-18 2009-06-17 P/gf-1 companion diagnostic methods and products.

Country Status (6)

Country Link
EP (1) EP2300825A4 (en)
JP (1) JP2011525241A (en)
CN (1) CN102224419A (en)
CA (1) CA2728449A1 (en)
MX (1) MX2010014228A (en)
WO (1) WO2009155381A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144975A0 (en) 1999-02-26 2002-06-30 Univ British Columbia A composition containing an antisense oligonucleotide
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP2542096B1 (en) * 2010-03-05 2015-07-15 Ophthalmopharma AG Nutraceutical chocolate or compound chocolate product
SG10201806648TA (en) 2011-07-01 2018-09-27 Ngm Biopharmaceuticals Inc Compositions, uses and methods for treatment of metabolic disorders and diseases
UY34812A (en) * 2012-05-18 2013-12-31 Teva Pharma METHOD FOR TREATMENT OF LUNG CANCER OF NON-SMALL CELLS
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9963494B2 (en) 2012-11-28 2018-05-08 Ngm Biopharmaceuticals, Inc. Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
CN105008548B (en) 2012-12-27 2020-11-27 恩格姆生物制药公司 Methods for modulating bile acid homeostasis and treating bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
CA2951153A1 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL251834B2 (en) 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
KR102652347B1 (en) * 2016-01-25 2024-03-27 사노피 Method for predicting outcome of treatment with aflibercept in patients suspected of having cancer by measurement of plasma biomarker levels
AU2017315459B2 (en) 2016-08-26 2023-06-29 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2022099465A1 (en) * 2020-11-10 2022-05-19 宁波奥丞生物科技有限公司 Hybridoma cell strain 9c1, plgf-1 monoclonal antibody, preparation method therefor and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049262A1 (en) * 1998-10-02 2003-03-13 Susan Love Methods for identification, diagnosis, and treatment of breast cancer
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
DE102005022047A1 (en) * 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Binding partner of the placental growth factor, in particular antibodies directed against the placental growth factor, their production and use
ATE493652T1 (en) * 2005-08-11 2011-01-15 Siemens Healthcare Diagnostics QUANTITATIVE ASSAY FOR PDGFR BETA IN BODY FLUID
CN101534865A (en) * 2005-10-19 2009-09-16 Ibc药品公司 Methods and compositions for generating bioactive assemblies of increased complexity and uses
WO2007056011A2 (en) * 2005-11-02 2007-05-18 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2007109571A2 (en) * 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
WO2008030283A1 (en) * 2006-05-31 2008-03-13 Beth Israel Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
US20080071151A1 (en) * 2006-06-30 2008-03-20 Sogin David C Method and Apparatus for Diagnosing Pre-eclampsia
MX2009004861A (en) * 2006-11-09 2009-05-21 Abbott Gmbh & Co Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor.

Also Published As

Publication number Publication date
EP2300825A1 (en) 2011-03-30
WO2009155381A1 (en) 2009-12-23
CN102224419A (en) 2011-10-19
EP2300825A4 (en) 2012-04-25
JP2011525241A (en) 2011-09-15
CA2728449A1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
MX2010014228A (en) P/gf-1 companion diagnostic methods and products.
WO2012061836A3 (en) Improved algorithm for detection of diabetes
WO2011015602A3 (en) Lung cancer biomarkers
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2009025852A3 (en) Methods of using mirna for detection of in vivo cell death
WO2010091049A3 (en) Diagnosis and treatment of cancer
WO2009009756A3 (en) Polyviologen boronic acid quenchers for use in analyte sensors
EP4303584A3 (en) Methods for detecting signatures of disease or conditions in bodily fluids
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
MX2011008938A (en) Antibodies to troponin i and methods of use thereof.
WO2009151628A3 (en) Monitoring tcr-b to determine hiv therapy and disease progression
MX345230B (en) Methods of diagnosing infectious disease pathogens and their drug sensitivity.
BR112013001752A2 (en) method of detecting disease or condition using phagocytic cells
WO2012009453A3 (en) Non-invasive monitoring of physiological conditions
WO2011095623A3 (en) miRNA IN THE DIAGNOSIS OF OVARIAN CANCER
WO2012054639A3 (en) Nmr systems and methods for the rapid detection of analytes
WO2012078623A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
MX361731B (en) Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity.
WO2012006056A3 (en) Ccr6 as a biomarker of alzheimer's disease
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease
WO2011133036A3 (en) Means and methods for determining risk of cardiovascular disease
WO2010032899A3 (en) Eno1-specific human antibody
WO2015069883A8 (en) Oxidized fraction of extracellular dna as a biomarker of stress and methods for using the same
GB2517345A (en) Anthracenyl-tetralactam macrocycles and their use in detecting a target saccharide
WO2012145399A3 (en) Methods of diagnosing cancer in a patient

Legal Events

Date Code Title Description
FA Abandonment or withdrawal